Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.
Lorena Lazo De La VegaHannah ComeauSarah SallanAlyaa Al-IbraheemiHersh V GuptaYvonne Y LiHarrison K TsaiWenjun KangAbigail WardAlanna J ChurchAeRang KimNavin R PintoMargaret E MacyLuke D MaeseAmit J SabnisAndrew D CherniackNeal I LindemanMegan E AndersonTabitha M CooneyKee Kiat YeoGregory H ReamanSteven G DuBoisNatalie B CollinsBruce E JohnsonKatherine A JanewaySuzanne J ForrestPublished in: JCO precision oncology (2022)
alterations were found in approximately 3% (41/1,395) of pediatric solid tumors, identifying a population of children with cancer who may be eligible and good candidates for trials evaluating FGFR-targeted therapy. Importantly, the genomic and clinical data from this study can help inform drug development in accordance with the Research to Accelerate Cures and Equity for Children Act.